Tirzepatide to be evaluated for improving metabolic outcomes post-adrenalectomy in mild autonomous cortisol secretion

Mild Autonomous Cortisol Secretion (MACS) is a prevalent endocrine condition characterized by the adrenal gland producing excessive cortisol, even without overt Cushing's syndrome. This chronic hypercortisolism significantly increases the risk of developing severe metabolic comorbidities, including hypertension, type 2 diabetes, and obesity. While surgical removal of the affected adrenal gland (adrenalectomy) is the standard treatment to normalize cortisol levels, a substantial proportion of patients continue to experience persistent metabolic dysfunction post-surgery. This ongoing challenge highlights a critical unmet need for adjunctive therapies that can effectively reverse or mitigate these lingering metabolic complications, even after the primary source of cortisol excess has been removed.

This randomized study is designed to evaluate the efficacy of tirzepatide as an adjunctive therapy following adrenalectomy in patients diagnosed with Mild Autonomous Cortisol Secretion (MACS). The trial will compare metabolic outcomes in patients receiving tirzepatide against those undergoing adrenalectomy alone. Participants will be randomized to one of two treatment arms after their adrenalectomy. The primary objective is to determine if tirzepatide can significantly improve various metabolic parameters, which are often resistant to resolution with surgery alone. Specific details regarding dosage, duration of treatment, and exact patient numbers (n) are not provided in this protocol description, but the study design aims for a robust comparison of post-surgical metabolic management strategies.